• Eng
  • 中文
  • 日本語
  • Span
  • Eng
  • 中文
  • 日本語
  • Span
Menu
Search Clinical Trials
Back to Search Results
Terminated/Withdrawn
Astellas Study ID
0367-CL-1201

A study to evaluate ASP0367 in participants with primary mitochondrial myopathy

Astellas Study ID
0367-CL-1201
Clinicaltrials.gov ID
NCT04641962
EUCTIS ID
N/A
EudraCT ID
N/A
jRCT ID
N/A
CN CDE ID
N/A
Get more information

Study summary

The purpose of this study was to evaluate the dose response of Bocidelpar on functional improvement relative to placebo, safety, and tolerability in participants with Primary Mitochondrial Myopathy.

Additional Study Details

Phase
Phase 2
Product
ASP0367
Product
Bocidelpar
Placebo
Type
Interventional
Masking
Triple (Participant, Care Provider, Investigator)
Enrollment number
34
Show Additional Study Details

Study documents

Scientific Results Summary
Available Language(s): English
Download Document(s)
Plain Language Summary
Available Language(s): English
Download Document(s)
Protocol
Available Language(s): English
Download Document(s)
Statistical Analysis Plan (SAP)
Available Language(s): English
Download Document(s)

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A study to evaluate ASP0367 in participants with primary mitochondrial myopathy? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Terminated
    Akron Children’s Hospital
    Akron, Ohio, United States, 44308
    Contact Us
    Terminated
    University of Texas Health Science Center at Hosuton
    Houston, Texas, United States, 77030
    Contact Us
    Terminated
    Columbia University Irving Medical Center
    New York, New York, United States, 10032
    Contact Us
    Terminated
    Massachusetts General Hospital
    Boston, Massachusetts, United States, 02114
    Contact Us
    Withdrawn
    Mayo Clinic
    Rochester, Minnesota, United States, 55905
    Contact Us
    Terminated
    Baylor College of Medicine
    Houston, Texas, United States, 77030
    Contact Us
    Terminated
    Cleveland Clinic
    Cleveland, Ohio, United States, 44195
    Contact Us
    Terminated
    Stanford University Medical Center
    Stanford, California, United States, 94305
    Contact Us
    Withdrawn
    Mayo Clinic Arizona
    Phoenix, Arizona, United States, 85054
    Contact Us
    Withdrawn
    Mayo Clinic Florida
    Jacksonville, Florida, United States, 32224
    Contact Us
    Terminated
    Children’s Hospital Colorado
    Aurora, Colorado, United States, 80045
    Contact Us
    Terminated
    Seattle Children's Hospital
    Seattle, Washington, United States, 98105
    Contact Us
    Terminated
    University of California, San Diego
    La Jolla, California, United States, 92093
    Contact Us
    Terminated
    Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania, United States, 19104
    Contact Us
    Trial info
    Follow Trial
    Age
    18 - 65 Years
    Diamond icon
    Condition
  • Primary Mitochondrial Myopathy (PMM)
    • Gender icon
    Sex
    Female & Male
    Calendar icon
    Trial Dates
    May 2021 - May 2024
    Additional Study Details
    Inclusion Criteria
    • Participant agrees and is able to adhere to the study requirements for the length of the study, including performing 6MWT.
    • Diagnosed with primary mitochondrial myopathy (PMM), consisting of the following:
    • Molecular genetic abnormality (i.e., nuclear or mitochondrial) known to be associated with mitochondrial dysfunction (such as, but not limited to, mitochondrial DNA (mtDNA) single deletions in chronic progressive external ophthalmoplegia (CPEO) and Kearns-Sayre syndrome (KSS); mtDNA m.3243 A > G pathogenic nuclear or mitochondrial genome variants demonstrated to cause primary mitochondrial disease), and
    • Participant reported symptoms (i.e., muscle weakness, fatigue and exercise intolerance) or physical examination findings of myopathy that are the predominant symptoms of the participant’s mitochondrial disorder.
      • Participant has been on stable dose regimen of coenzyme Q10 (CoQ10), carnitine, creatine, or other mitochondrial disease- focused vitamins or supplemental therapies for the treatment of symptoms of the mitochondrial disease for at least 3 months prior to randomization and intends to stay on a stable dose for duration of study period.
      • Participant has been on stable exercise regimen within 4 weeks prior to randomization and intends to stay on a stable regimen for duration of study period (for participants who participate in a regular exercise regimen).
      • Female participant is not pregnant and at least one of the following conditions apply:
    • Not a woman of childbearing potential (WOCBP).
    • WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 30 days after final study treatment administration.
      • Female participant must agree not to breastfeed starting at screening and throughout the study period and for 30 days after final study treatment administration.
      • Female participant must not donate ova starting at first dose of IP and throughout the study period and for 30 days after final study treatment administration.
      • Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 30 days after final study treatment administration.
      • Male participant must not donate sperm during the treatment period and for 30 days after final study treatment administration.
      • Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 30 days after final study treatment administration.
      • Participant agrees not to participate in another interventional study while participating in the present study.
    MaximizeExclusion Criteria
    • Participant has additional signs and/or symptoms due to non-myopathic process (e.g., cerebellar dysfunctions, movement disorder, peripheral neuropathy, stroke or other) or a gait problem not attributed to the myopathy that would interfere with the participant's performance during 6MWT or 5 times sit to stand (5XSTS).
    • Participant has received any investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening.
    • Participant has any condition, which makes the participant unsuitable for study participation.
    • Participant has cardiac troponin I (cTnI) > upper limit of normal (ULN) at screening.
    • Participant has estimated glomerular filtration rate (eGFR) calculated by the chronic kidney disease epidemiology collaboration equation < 60 milliliter per minute per 1.73-meter square at screening or a history of chronic kidney disease stage 3 or greater.
    • Participant has at screening*: total bilirubin (TBL) > ULN or transaminase(s) (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) > ULN in the absence of elevations in CK. Participants who have a slightly elevated TBL and/or ALT and/or AST and are suitable candidates for the study may be enrolled after discussion of the case with the medical monitor and completion of further evaluation as warranted.
    • Participant has psychiatric conditions such as schizophrenia, bipolar disorder or major depressive disorder that has not been under control within 3 months prior to screening.
    • Participant has a history of suicide attempt, suicidal behavior or has any suicidal ideation within 1 year prior to screening that meets criteria at a level of 4 or 5 by using the Columbia- Suicide Severity Rating Scale (C-SSRS) or who is at significant risk to commit suicide.
    • Participant has severe behavioral or cognitive problems that preclude participation in the study.
    • Participant has undergone an in-patient hospitalization that precludes participation in the study, within the 30 days prior to the randomization.
    • Participant has a planned hospitalization or a surgical procedure during the study, which may affect the study assessments.
    • Participant has clinically significant and unstable respiratory disease and/or cardiac disease (medical history or current clinical findings), or prior interventional cardiac procedure (e.g. cardiac catheterization, angioplasty/percutaneous coronary intervention, balloon valvuloplasty, etc.) within 3 months prior to randomization. Participants with pacemakers are allowed in the study per investigator's discretion and after discussion with the medical monitor, and as long as it is used for prevention and there is no underlying cardiac dysfunction.
    • Participant has a corrected mean QT interval using Fridericia's correction (QTcF) > 450 msec for male participants and > 480 msec for female participants at screening or randomization. If QTcF exceeds these limits, one additional triplicate ECG can be repeated on the same day in order to determine the participant's eligibility.
    • ECG evidence of acute ischemia, atrial fibrillation or active conduction system abnormalities. The following conduction system abnormalities may be permitted per the investigator’s discretion, only after discussing the case with the medical monitor:
    • First degree atrioventricular (AV)
    • block
    • Second degree AV-block Type 1 (Mobitz Type 1/Wenckebach type)
    • Right bundle branch block
    • Left fascicular block
    • Bi-fascicular block
      • Participant requires any ventilatory support, inclusive of any respiratory device to support breathing such as home ventilators and any form of non-invasive positive pressure ventilation (including continuous positive airway pressure [CPAP], bilevel positive airway pressure [BiPAP], and average volume-assured pressure support [AVAPS]). Participants who require oxygen therapy (even by low flow nasal cannula [LFNC]) are not candidates for this study.
      • Participant has severe vision impairment that may interfere with their ability to complete all study requirements.
      • Participant has an intractable seizure disorder that may interfere with their ability to complete all study requirements.
      • Active malignancy or any other cancer from which the participant has been disease-free for < 5 years, except for curative treated localized non-melanoma skin cancer (e.g., basal cell or squamous cell carcinoma).
      • Participant has a solid organ transplant and/or is currently receiving treatment with therapy for immunosuppression.
      • Participant has severe scoliosis or kyphoscoliosis that significantly impair respiratory capacity and pulmonary function tests or limit positioning due to pain who would be likely to require orthopedic surgical intervention within a year after study randomization.
      • Participant has a positive test for human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection at screening.
      • Participant has previously received Bocidelpar.
      • Participant has a history of active substance abuse within 1 year prior to randomization.
      • Participant has used any peroxisome proliferator-activated receptor (PPAR) ligands such as fibrates and thiazolidinediones within 4 weeks prior to randomization.
      • Participant has initiated the use of CoQ10, carnitine, creatine or other mitochondrial disease-focused supplements for the treatment of symptoms of the mitochondrial disease within 3 months prior to study randomization.
      • Participant has a known or suspected hypersensitivity to Bocidelpar or any components of the formulation used.
      • Participant has symptomatic coronavirus disease 2019 (COVID-19) infection within 3 months prior to study randomization that required treatment (Monoclonal antibodies, ventilator support, hospitalization) and/or led to long-term sequelae or lingering symptoms.
      • Participant has body mass index (BMI) below 17 kg/ m^2 or above 35 kg/ m^2 at screening.
      • Participant has signs or symptoms of bulbar weakness, such as dysphagia, dysphonia, hoarseness or drooling/sialorrhea, due to either neuropathy or myopathy.

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    Find a Trial
    2

    Why are Clinical Trials Important?

    Learn More
    3

    Why Participate in a Clinical Trial?

    Discover More